A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

NCT02469155 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

696

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ITI-007
DRUG: Risperidone
DRUG: Placebo

Sponsor

Intra-Cellular Therapies, Inc.